Khosro Farhad1,2. 1. Department of Neurology at Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, WAC 835, Boston, MA, 02114, USA. kfarhad@mgh.harvard.edu. 2. Wentworth Health Partners, 121 Corporate Drive, Portsmouth, NH, 03801, USA. kfarhad@mgh.harvard.edu.
Abstract
PURPOSE OF REVIEW: Small fiber neuropathy (SFN) could cause significant morbidity due to neuropathic pain and autonomic dysfunction. SFN is underdiagnosed and the knowledge on the condition is limited among general public and health care professionals. This review is intended to enhance the understanding of SFN symptoms, causes, diagnostic tools, and therapeutic options. RECENT FINDINGS: There is evidence of SFN in up to 40% patients with fibromyalgia. The causes of SFN are glucose metabolism defect, dysimmune, gluten sensitivity and celiac disease, monoclonal gammopathy, vitamin deficiencies, toxic agents, cancer, and unknown etiology. Auto-antibodies targeting neuronal antigens trisulfated heparin disaccharide (TS-HDS) and fibroblast growth factor 3 (FGFR3) are found in up to 20% of patients with SFN. Treatment of SFN includes treating the etiology and managing symptoms. SFN should be considered in patients with wide-spread body pain. The search for known causes of SFN is a crucial step in disease management.
PURPOSE OF REVIEW: Small fiber neuropathy (SFN) could cause significant morbidity due to neuropathic pain and autonomic dysfunction. SFN is underdiagnosed and the knowledge on the condition is limited among general public and health care professionals. This review is intended to enhance the understanding of SFN symptoms, causes, diagnostic tools, and therapeutic options. RECENT FINDINGS: There is evidence of SFN in up to 40% patients with fibromyalgia. The causes of SFN are glucose metabolism defect, dysimmune, gluten sensitivity and celiac disease, monoclonal gammopathy, vitamin deficiencies, toxic agents, cancer, and unknown etiology. Auto-antibodies targeting neuronal antigens trisulfated heparin disaccharide (TS-HDS) and fibroblast growth factor 3 (FGFR3) are found in up to 20% of patients with SFN. Treatment of SFN includes treating the etiology and managing symptoms. SFN should be considered in patients with wide-spread body pain. The search for known causes of SFN is a crucial step in disease management.
Entities:
Keywords:
Amyloidosis; Autonomic neuropathy; FGFR3; Fibromyalgia; Small fiber neuropathy; TS-HDS
Authors: G Lauria; S T Hsieh; O Johansson; W R Kennedy; J M Leger; S I Mellgren; M Nolano; I S J Merkies; M Polydefkis; A G Smith; C Sommer; J Valls-Solé Journal: Eur J Neurol Date: 2010-07 Impact factor: 6.089
Authors: Jinny O Tavee; Karen Karwa; Zubair Ahmed; Nicolas Thompson; Joseph Parambil; Daniel A Culver Journal: Respir Med Date: 2017-03-09 Impact factor: 3.415
Authors: Ole Jakob Vilholm; Alex Alban Christensen; Ahmed Hussein Zedan; Mustapha Itani Journal: Basic Clin Pharmacol Toxicol Date: 2014-05-20 Impact factor: 4.080
Authors: M I Periquet; V Novak; M P Collins; H N Nagaraja; S Erdem; S M Nash; M L Freimer; Z Sahenk; J T Kissel; J R Mendell Journal: Neurology Date: 1999-11-10 Impact factor: 9.910
Authors: Dan Ziegler; Nikolaos Papanas; Andrey Zhivov; Stephan Allgeier; Karsten Winter; Iris Ziegler; Jutta Brüggemann; Alexander Strom; Sabine Peschel; Bernd Köhler; Oliver Stachs; Rudolf F Guthoff; Michael Roden Journal: Diabetes Date: 2014-02-26 Impact factor: 9.461
Authors: W Singer; J M Spies; J McArthur; J Low; J W Griffin; K K Nickander; V Gordon; P A Low Journal: Neurology Date: 2004-02-24 Impact factor: 9.910